Far-UVC Research Summary

Key studies on 222nm far-UVC safety and efficacy. The science behind the technology.

Columbia University (2018)

Dr. David Brenner's lab demonstrated that 222nm far-UVC inactivates airborne H1N1 influenza virus without damaging human skin cells. Published in Scientific Reports. The foundational study.

Kobe University (2020)

Japanese study confirmed no corneal damage at 222nm exposure within ACGIH limits. 40+ subjects over extended exposure periods. Critical for eye safety validation.

Nature (2022)

Room-sized chamber study: 98% reduction of airborne pathogens within 5 minutes of continuous 222nm exposure. Equivalent to 184 air changes per hour. The headline result.

St. Andrews (2022)

Real-world hospital study. Far-UVC fixtures installed in occupied patient rooms. Significant reduction in surface and airborne bacteria. First major real-world deployment data.

Safety Consensus (2023)

Meta-analysis of 50+ studies. ACGIH TLV of 22 mJ/cm2 for 222nm confirmed as protective. No adverse skin or eye effects reported at regulated exposure levels across all published studies.